Sitagliptin's Neuroprotective Role in Type 2 Diabetes and Alzheimer's Disease
Author Information
Author(s): Mani Vasudevan, Arfeen Minhajul, Akhtar Ansab
Primary Institution: Qassim University
Hypothesis
Can sitagliptin provide neuroprotective benefits in type 2 diabetes mellitus that may also impact Alzheimer's disease?
Conclusion
Sitagliptin significantly reduces brain enzyme levels linked to Alzheimer's and improves neuroprotective markers in type 2 diabetes-induced rats.
Supporting Evidence
- Sitagliptin reduced brain enzyme levels linked to Alzheimer's disease.
- It improved oxidative stress markers in diabetic rats.
- Sitagliptin treatment enhanced plasma insulin levels.
- Neuroinflammatory markers were significantly reduced with sitagliptin treatment.
- Sitagliptin showed potential binding affinity to key neuroprotective targets.
Takeaway
Sitagliptin, a diabetes medication, helps protect the brain from damage caused by diabetes, which can also lead to Alzheimer's disease.
Methodology
Rats were induced with type 2 diabetes and treated with sitagliptin to evaluate its effects on brain enzymes and neuroinflammation.
Limitations
The study lacks molecular dynamics simulations and in vitro evaluations of the target enzymes.
Participant Demographics
30 adult male Sprague Dawley rats, aged 11 to 12 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website